Deruxtecan-d5
Deruxtecan-d5 is deuterium labeled Deruxtecan. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
Product Specifications
Product Name Alternative
MC-GGFG-DXD-d5
UNSPSC
12352005
Target
Drug-Linker Conjugates for ADC; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Antibody-drug Conjugate/ADC Related; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.40
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)C([2H])([2H])C([2H])([2H])[2H])=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O)=O
Molecular Formula
C52H51D5FN9O13
Molecular Weight
1039.08
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.|[3]Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107 (7) :1039-46.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY424744 100 µg
IL3RB (CSF2RB) (NM_000395) Human Over-expression Lysate
Sign In for Pricing
View Details 
LY420557 100 µg
beta Catenin (CTNNB1) (NM_001098209) Human Over-expression Lysate
Sign In for Pricing
View Details 
